Osteoporosis
Treatment sequence key for optimal management of osteoporosis
Osteoporosis is a common disease that remains significantly underdiagnosed and undertreated.
Should a prior fracture be a requirement for initiating osteoporosis treatment with an anabolic agent?
Click here to read the cover story, “Treatment sequence key for optimal management of osteoporosis”
Choice of osteoporosis drug sequence has ‘important clinical consequences’
DESTIN, Fla. — Understanding when to switch from one class of drugs to another is critical to maintaining bone health and preventing fractures in osteoporosis, according to data presented at the Congress of Clinical Rheumatology East.
VIDEO: Consider social determinants of health to increase osteoporosis screening
SAN DIEGO — In this video exclusive, Jonathan D. Leffert, MD, talks with Nicole C. Wright, PhD, MPH, about health disparities in metabolic bone disease.
Abaloparatide increases BMD, improves bone turnover markers in men with osteoporosis
SAN DIEGO — Men with osteoporosis receiving daily injections of abaloparatide had greater increases in bone mineral density at the lumbar spine, total hip and femoral neck at 12 months compared with placebo, according to a speaker.
FDA clear artificial intelligence software measuring BMD, fractures
The FDA has given 510(k) clearance for artificial intelligence software developed to support providers in the evaluation and assessment of musculoskeletal disease for older adults, according to an industry press release.
VIDEO: Stephanie Faubion, MD, reports on latest updates in women’s health
CHICAGO — In this video interview with Healio, Stephanie Faubion, MD, MBA, FACP, NCMP, IF, highlights recent research on women’s health, which she discussed during her presentation here.
Bone strain index may add to fracture risk prediction for postmenopausal women
Postmenopausal women with higher bone strain index values at the spine, neck and total hip are more likely to have incident fragility fractures vs. those with a lower bone strain index, according to study findings published in Bone.
BLOG: My own ‘noncompliance’ with osteoporosis therapy
As I was searching through some old archives and memorabilia, I came across this pocket calendar (Figures 1-4).
Risk for osteonecrosis of the jaw higher with denosumab vs. bisphosphonates
Adults with osteoporosis have a higher risk for developing osteonecrosis of the jaw with denosumab therapy compared with bisphosphonates, according to study findings published in the Journal of Bone and Mineral Research.